Industry Urges Caution Over Japan HTA Plans
This article was originally published in PharmAsia News
Executive Summary
Japan may have decided to dip an exploratory toe in the waters of health technology assessment, but the research-based pharma industry is continuing to voice early caution over potential shortcomings in methodology and expertise, and to stress the need for a holistic approach.
You may also be interested in...
Pricey New HCV, Cancer Drugs Push Up Japan’s Health Care Costs
Japan has reported big rises in drug costs covered by its national health insurance scheme, driven in large part by hepatitis C and cancer, adding weight to ongoing discussions of possible new cost containment measures.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.